References
- Solberg L., Oles K., Kimlinger T., Tefferi A., Katzmann J., Li C.-Y. A new murine monoclonal antibody for the diagnosis of erythroleukemia. American Journal of Clinical Pathology 1990; 93: 387–390
- Witzig T., Gertz M., Lust J., Kyle R., O'Fallon W., Greipp P. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88: 1780–1787
- Garton J., Gertz M., Witzig T., Greipp P., Lust J., Schroeder G., Kyle R. Epoetin alfa for the treatment of the anemia of multiple myeloma. Archives of Internal Medicine 1995; 155: 2069–2074
- Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine 1990; 322: 1693–1699
- Greipp P., Lust J., O'Fallon M., Katzmann J., Witzig T., Kyle R. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
- San Miguel J., García-Sanz R., González M., Moro M., Hernández J., Ortega F., Borrego D., Carnero M., Casanova F., Jiménez R., Portero J., Orfao A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455
- Greipp P., Witzig T., Gonchoroff N. Immunofluorescent plasma cell labeling indices using a monoclonal antibody (BU-1). American Journal of Hematology 1985; 20: 289–292
- Beguin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leukemia and Lymphoma 1995; 18: 413–421
- Beguin Y., Yerna M., Loo M., Weber M., Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. British Journal of Haematology 1992; 82: 648–653
- Aoki I., Nishijima K., Homori M., Nakahara K., Higashi K., Ishikawa K. Responsiveness of bone marrow ery-throid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. British Journal of Haematology 1992; 81
- Jensen I., Hokland M., Hokland P. A quantitative evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow cytometry. Leukemia Research 1993; 17: 839–846
- Ifudu O., Feldman J., Friedman E. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. New England Journal of Medicine 1996; 334: 420–425
- Lacombe C. Resistance to erythropoietin. New England Journal of Medicine 1996; 334: 660–662
- Schrciber S., Howaldt S., Schnoor M., Nikolaus S., Bauditz J., Gasche C., Lochs H., Raedler A. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. New England Journal of Medicine 1996; 334: 619–623
- Lichtenstein A., Berenson J., Norman D., Chang M.-P., Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74: 1266–1273
- Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A., Lansdorp P., Di Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–387
- Lust J. Role of cytokines in the pathogenesis of monoclonal gammopathies. Mayo Clinic Proceedings 1994; 69: 691–697
- Lust J., Donovan K., Lacy M., Witzig T. Aberrant expression of IL-1β is a critical genetic event in the transition of MGUS to myeloma. Blood 1996; 88(suppl 1)104a
- Westendorf J., Ahmann G., Greipp P., Witzig T., Lust J., Jelinek D. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866–876